Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes by 
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Monitoring on A1C, Glucose Proﬁles, and
Hypoglycemia in Adults With Type 1
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THE JUVENILE DIABETES RESEARCH
FOUNDATION CONTINUOUS GLUCOSE
MONITORING STUDY GROUP*
OBJECTIVE — To evaluate long-term effects of continuous glucose monitoring (CGM) in
intensively treated adults with type 1 diabetes.
RESEARCH DESIGN AND METHODS — We studied 83 of 86 individuals 25 years
of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a
subsequent 6-month extension study.
RESULTS — After 12 months, median CGM use was 6.8 days per week. Mean change in A1C
level from baseline to 12 months was 0.4  0.6% (P  0.001) in subjects with baseline A1C
7.0%. A1C remained stable at 6.4% in those with baseline A1C 7.0%. The incidence rate of
severehypoglycemiawas21.8and7.1eventsper100person-yearsintheﬁrstandlast6months,
respectively. Time per day with glucose levels in the range of 71–180 mg/dl increased signiﬁ-
cantly (P  0.02) from baseline to 12 months.
CONCLUSIONS — In intensively treated adults with type 1 diabetes, CGM use and beneﬁt
can be sustained for 12 months.
Diabetes Care 32:2047–2049, 2009
I
n a 6-month randomized trial of in-
tensively treated individuals with
type 1 diabetes and baseline A1C
7.0%, adults 25 years of age bene-
ﬁted from use of continuous glucose
monitoring (CGM) compared with
adults using conventional blood glu-
cose monitoring (1). In a contempora-
neous parallel study of individuals with
type 1 diabetes who had A1C levels
7.0%, those in the CGM group had a
reduction in biochemical hypoglycemia
compared with those in the control
group while maintaining A1C levels in
the target range (2). This report de-
scribesthe12-monthfollow-upofadult
subjects in the two randomized trials’
CGM groups.
RESEARCH DESIGN AND
METHODS— The protocol has been
described in detail (1–3). We analyzed
12-month follow-up data for 83 of the
86 adults (25 years of age) who were
initially randomized to the CGM group
in either the 7.0% (n  49) or 7.0%
(n  34) baseline A1C cohorts; 2 sub-
jects discontinued study participation
during the ﬁrst 6 months and one after
completion of the 9-month visit. An in-
sulin pump was used by 75 (90%) sub-
jects and multiple daily injections
(MDIs) of insulin by 8 (10%). Subjects
were provided with either a DexCom
SEVEN(DexCom,SanDiego,CA),Min-
iMed Paradigm REAL-Time System
(Medtronic MiniMed, Northridge, CA),
or FreeStyle Navigator (Abbott Diabetes
Care, Alameda, CA). Follow-up visits
during the extension study occurred at
9 and 12 months postrandomization.
A1C was measured at the University of
Minnesota using the Tosoh A1C 2.2 Plus
GlycohemoglobinAnalyzermethod(4).Se-
vere hypoglycemia was deﬁned as an event
that required assistance from another per-
son to administer resuscitative actions (5).
The amount of CGM use was deter-
mined from CGM downloads. Statistical
testing was performed with a paired t test
formeasureswithanapproximatenormal
distribution and with a signed-rank test
for other measures. Changes in glucose
variability were evaluated in least squares
regression models based on van der
Waerden rank normal scores.
RESULTS— MedianCGMusewas7.0
days/week (interquartile range 6.3–7.0)
at 6 months and 6.8 days/week (inter-
quartile range 5.8–7.0) at 12 months (see
online appendix supplemental Table S1,
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc09-0846/DC1). Use at
12 months did not vary with baseline A1C
level (Spearman r  0.10; P  0.38).
Among subjects with baseline A1C
7.0%, mean change in A1C from base-
line to 12 months was 0.4  0.6% (P 
0.001), similar to the change from base-
line to 6 months. The reduction in A1C
occurred mainly in the ﬁrst 8 weeks and
then remained relatively stable through
thenext44weeks(supplementalFig.S1).
Among subjects with baseline A1C
7.0%, A1C remained within the target
range over the entire 12 months of the
study (6.4, 6.3, and 6.4% at baseline, 6
months, and 12 months, respectively;
P  0.42 for change from baseline to 12
months).
A severe hypoglycemic event was ex-
periencedby8(10%)ofthe83subjects(9
events) during the ﬁrst 6 months and 3
subjects (4%; 3 events) in the second 6
months. The rate of severe hypoglycemic
events fell from 21.8 events per 100 per-
son-years during the ﬁrst 6 months to 7.1
events per 100 person-years (95% CI
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(P  0.18). The rate was not associated
with baseline A1C (Spearman r 
0.004;P0.97).Insubjectswithbase-
line A1C 7%, the incidence fell from
20.5 events per 100 person-years in the
ﬁrst 6 months to 12.1 events per 100 per-
son-years in the second 6 months,
whereas in the A1C 7% cohort, the in-
cidencefellfrom23.6eventsper100per-
son-years to no events during the second
6 months (supplemental Fig. S2).
The median amount of time per day
withglucoseintherangeof71–180mg/dl
increased signiﬁcantly (P  0.02) from
baseline to 12 months, reﬂecting a de-
crease in both hypoglycemia and hyper-
glycemia. Similar trends were seen both
insubjectswithbaselineA1C7.0%and
in those with baseline A1C 7.0% (Table
1). The increase in time in range was seen
during both daytime and nighttime (sup-
plemental Table S2). Variability assessed
with the SD of glucose values (P  0.02)
and mean amplitude of glycemic excur-
sions (P  0.03) was reduced with CGM
use from baseline to 12 months. Body
weight, daily insulin dose, and frequency
of daily blood glucose meter tests did not
change meaningfully during the study.
CONCLUSIONS — In this 6-month
extension to a randomized clinical trial,
we found that most adults 25 years of
age continued to use CGM on a daily or
near-daily basis and had sustained bene-
ﬁts of improved glucose control noted by
A1C levels and the amount of time sensor
glucose values were in the target range.
These beneﬁts persisted despite less-
intensive follow up, designed to approxi-
mate usual clinical practice, than that
during the 6-month randomized phase of
the study.
An additional important observation
was the remarkably low rate of severe hy-
poglycemic events during the extension
phase of the study. The rate of severe hy-
poglycemia in our CGM subjects with a
mean A1C of 6.8% during the 6-month
extensionphasewasmarkedlylowerthan
the rate of severe hypoglycemia in the Di-
abetes Control and Complications Trial
(DCCT) intensive treatment group,
which had mean A1C of 7.1% (7 vs. 62
events per 100 person-years) (6). The to-
tal absence of severe hypoglycemia dur-
ing the second 6 months of the study in
the subjects who had a baseline A1C
7.0% is particularly striking, especially
because these subjects were able to main-
tain a mean A1C of 6.4%.
Itispossiblethatthedeclineinsevere
hypoglycemic events during the second 6
months of the study resulted from learn-
ing from prior experience, including ap-
propriate setting of the low alarms,
glucose targets, and titration of basal and
bolus insulin doses. It is also intriguing to
speculate that the reduction in exposure
to biochemical hypoglycemia over the 12
months of the study may have protected
subjectsfromseverehypoglycemicevents
by enhancing their counterregulatory
hormonedefensemechanismsagainsthy-
poglycemia (7).
Our ﬁndings demonstrate that the
beneﬁts of CGM can be sustained for at
least 12 months in motivated adults with
type1diabetespracticingintensivediabe-
tes management. In such individuals,
CGMprovidestheabilitytoachievetarget
A1C levels much more safely than previ-
ously reported.
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